Bioqual
Private Company
Funding information not available
Overview
Bioqual is a well-established, privately-held preclinical CRO with over four decades of experience, offering specialized research services in infectious diseases and oncology. Its core value proposition lies in its extensive animal model capabilities, including non-human primates, and advanced in vitro and BSL-3 laboratory services. The company has a strong track record, having completed 1,485 studies for 269 unique clients in the last five years, positioning it as a key partner for high-stakes translational research.
Technology Platform
Integrated preclinical research platform featuring established small and large animal models (including non-human primates), comprehensive in vitro assay services (immunoassays, cell-based assays, high-throughput screening), and advanced BSL-3 high-containment laboratory facilities for work with high-risk pathogens.
Opportunities
Risk Factors
Competitive Landscape
Bioqual competes in the fragmented preclinical CRO market against large, full-service players (e.g., Charles River, Labcorp) and other niche specialists. Its differentiation lies in its deep expertise in infectious disease models, BSL-3 containment, and established non-human primate resources, catering to a high-complexity segment of the market.